Impact of the pandemic on routine immunisations for vaccine-preventable diseases
Routine childhood immunisation programmes have been disrupted because of Covid-19 and their implementation should be prioritised.
By
Routine childhood immunisation programmes have been disrupted because of Covid-19 and their implementation should be prioritised.
ByAt least four long Covid-19 drug trial readouts are expected in 2022 that could shape the future of the therapeutic…
ByIn an exclusive, Clinical Trials Arena dives into Australia’s trial activity data to find out how the pandemic impacted the…
ByModerna CEO Stéphane Bancel also said an Omicron-specific Covid-19 vaccine will enter clinical development in a matter of weeks.
ByThe trial will enrol 90 subjects to assess the safety, tolerability, and immunogenicity of three dose levels of the vaccine.
The trial intends to enrol up to 30 subjects who are aged over 18 years with long Covid-19.
Novartis confirmed plans to in-license ensovibep from Molecular Partners for nearly $163m.
The trial will assess the tolerability, safety, efficacy and PK of two varying doses of suramin in adult LCS patients.